Shopping Cart
- Remove All
- Your shopping cart is currently empty
Luxeptinib (CG-806) is a novel pan-FLT3/pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells [1][2][3][4].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,140 | 6-8 weeks | |
50 mg | $1,490 | 6-8 weeks | |
100 mg | $2,440 | 6-8 weeks |
Description | Luxeptinib (CG-806) is a novel pan-FLT3/pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induces cell cycle arrest, apoptosis, or autophagy in acute myeloid leukemia cells [1][2][3][4]. |
In vitro | Luxeptinib (MEC-1 CLL cells; 0.1~10 μM; 72 hours) inhibits cell proliferation with an IC50 of 32 nM[1]. It inhibits BCR signaling-induced phosphorylation of BTK, PLCg2, AKT, ERK1/2, and S6 ribosomal protein, and strongly suppresses SYK phosphorylation in primary chronic lymphocytic leukemia (CLL) cells[1]. Luxeptinib (MV4-11 cells; 500 pM; 1 hour) completely inhibits phosphorylation of FLT3 and STAT5[2]. |
Molecular Weight | 495.43 |
Formula | C25H17F4N5O2 |
Cas No. | 1616428-23-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (252.31 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.